FDA: New Warning for Procrit, Epogen, Aranesp

New data show that the way Procrit, Epogen, and Aranesp are used in patients with chronic kidney disease puts them at risk of heart attacks, stroke, and death. More conservative dosing is needed.

Click here to read the full story.

Post a Comment
 

 
Comments
No comments yet!
Inergize Digital This site is hosted and managed by Inergize Digital.
   

WTVQ.com supports children's privacy rights. All persons under the age of 13 MUST have parental permission to use this website and direct parental supervision is strongly recommended.